

CURRICULUM VITAE

NAME: Zhi-Min Yuan

ADDRESS: 59 Three Lakes Drive, San Antonio, TX 78248

EDUCATION:

1978-1982	Internal Medicine	M.D.	Jiangxi Medical College, China
1983-1985	Pharmacology	M.S.	Hunan Medical University, China.
1989-1993	Biomedical Chemistry	Ph.D.	University of Maryland

POSTDOCTORAL TRAINING:

1987-1989	Drug Metabolism	University of Maryland	Research Associate
1993-1994	Cancer	Harvard Medical School Dana-Farber Cancer Institute	Research Associate

Internships and Residencies:

1982-1983	Resident in Medicine	The First Hospital of Jiangxi Medical College, China.
-----------	----------------------	---

ACADEMIC APPOINTMENTS:

2008-	Professor	Department of Radiation Oncology	UTHSCSA
2002-2008	Associate Prof.	Genetics and Complex Disease	Harvard School of Public Health
1998-2002	Assistant Prof.	Cancer Cell Biology	Harvard School of Public Health
1994-1998	Instructor	Adult Oncology	Dana-Farber Cancer Institute

HONORS AND DISTINCTIONS:

2000-2004	American Cancer Society Junior Faculty Award
2000	Mentor of the Year, Siemen Foundation
2002-present	Guest Professor, Cancer Center, Sun Yet-sen University, China
2002-present	Guest Professor, Cancer Center, Xianya Hospital Central South University, China

MAJOR PROFESSIONAL SERVICE:

NIH Breast Cancer Pathology	Member (ad hoc)	2002
Department of Energy	Member (ad hoc)	2003
NIH Cancer Etiology Study section	Member (ad hoc)	2006
National Science Foundation	Member (ad hoc)	2006
Department of Defense	Member (ad hoc)	2007
Philip Morris	Member (ad hoc)	2007
NIH Cancer Etiology Study section	Member (ad hoc)	2008
NIH Cancer Biology Study section	Member (ad hoc)	2008
Department of Defense	Member (ad hoc)	2008
Department of Defense	Member (ad hoc)	2009
Department of Defense	Member (ad hoc)	2010

NIH Cancer Etiology Study section Regular Member		2010-
International		
The Israel Science Foundation	Member (ad hoc)	2000
The Israel Science Foundation	Member (ad hoc)	2001
The Israel Science Foundation	Member (ad hoc)	2004
The Wellcome Trust	Member (ad hoc)	2006
The Wellcome Trust	Member (ad hoc)	2008
The Wellcome Trust	Member (ad hoc)	2009

PROFESSIONAL SOCIETIES:

1994-present	Member, American Cancer Society
2000-present	Member, American Association for Radiation Research

MAJOR ADMINISTRATIVE RESPONSIBILITIES:

1999-2006	Curriculum Committee, Division of Biological Science, Harvard School of Public Health
1999-2007	The Rotation Committee, DBS, Harvard School of Public Health
2000-2003	The Committee on Education Policy, Harvard School of Public Health
2002-2008	The Recruitment Committee, DBS, Harvard School of Public Health
2006-2008	The Preliminary Examination Committee, Chair, DBS, Harvard School of Public Health

MAJOR RESEARCH INTERESTS:

1. Elucidation of mechanisms for regulation of tumor suppresser p53;
2. Characterization of c-Abl tyrosine kinase in stress response;
3. Investigation of mechanisms underlying the correlation of aging and cancer with a focus on the importance of the tissue microenvironment.

RESEARCH SUPPORT (as PI only):

Current support

2 R01 CA85679-05	NIH/NCI	08/1/04 – 07/31/10	Molecular Basis of p53-Induction to DNA Damage
RO1 CA125144	NIH/NCI	07/08-07/2013	Functional interaction of beclin 1/class III PI-3 kinase and p53 in breast tumorigenesis
DOE 110976	DOE	07/15/09-07/15/2012	The c-Abl signaling network in radio-adaptive response

Completed research support

No grant number	NIEHS	07/01/07 - 06/30/08	Arsenite predisposes cells to transformation by inactivating p53
2005-2007	DOE		Low dose IR creates an oncogenic microenvironment by inducing premature senescence in stromal fibroblasts
2000-2003	ACS		Role for p300/CBP in regulation of p53 activation by stress
1998-2003	NIH (R29)		Role for c-Abl kinase in DNA damage-induced responses
2001-2004	NIH (RO1)		Mechanism of p53 induction in response to DNA damage
2001	Milton, Harvard Medical School		Regulation of p53 stability
2002-2003	Pfizer Inc.		Identification and characterization of proteins that regulate p53 turn over
Pending:			
R01	NIH/NCI		The importance of epithelia/fibroblast interaction in senescent response to IR
RO1	NIH/NCI		A novel p53-based cancer therapy

TEACHING EXPERIENCE

Date	Title	Institution	Experience
2000-2008	Introduction of Cancer Cell Biology (GCD210)	HSPH	Head instructor
2001-2008	Introduction of Toxicology (EH210)	HSPH	Lecturer
2008	Molecular Oncology/Radiobiology	UTHSCSA	Head Instructor
2010	Molecular Oncology/Radiobiology	UTHSCSA	Head Instructor

Doctoral Trainees

2001-2004	Dmitri Wiederschain
2002-2005	Kelvin Tsai
2002-2005	Jeremy Stuart
2003-2006	Maha Ali Al-Mohaya
2003-2008	Mihee Kim
2003-2008	Vanessa Lopez
2007-	Shireen Sarraf
2008-	Rajuli Lall
2009-	Miriam Shadfan
2010-	Doo Eun Choi

Postdoctoral Trainees

1998	Xiangao Sun	Kanazawa University, Japan, Ph.D. (1997).
1999-2000	Dongli Chen	Beijing Medical University, China, M.D. (1996)
1998-2002	Jijie Gu	Peking Union Medical University, China, Ph.D. (1995)
2000-2002	Linghu Nie	Peking Union Medical University, China, Ph.D. (1998)
2000-2003	Hiroyuki Kitao	Koyto University, Japan, Ph.D. (1999)
2000-2004	Hidehiko Kawai	Hiroshima University, Japan, Ph.D. (2000)
2002-2003	HongYen Zhu	Nagoya University, Japan, Ph.D. (2001)
2003=2004	Xixiang Tang	Hunan Medical University, M.D. (2001)
2004-2006	Chufan Li	Beijing Medical University, Ph.D. (2004)
2004-2007	Yelin Huang	Sun Yet-sen University, Ph.D. (2003)
2005-2006	Jeremy Stuart	Harvard School of Public Health, ScD, (2005)
2006-2008	Kevin McHenry	University of Illinois in Chicago, Ph.D. (2006)
2006-	Weiqi Zeng	Hunan Normal University, Ph.D. (2006)
2008-2010	Tsutomu Mori	Fukushima Medical University, Japna. M.D. Ph.D. (1992)
2008-2010	Seog-Jin Seo	Seoul National University, Korea, Ph.D. (2005)
2008-	Su Hang	Sun Yat-sen University, China, Ph.D. (2008)
2008-2010	Feng Fang	South Central University Medical School, M.D. (2006)
2008-	Song Long	South Central University Medical School, M.D. (2007)
2009-	Teng Xu	Sun Yat-sen University, China, Ph.D. (2009)
2008-	Suthakar Ganaphy	Annamalai University, India (2006)

Student Exam and Advisory committees

1999-2003	Hickman, Mark (DBS, Ph.D. program), Thesis Advisory Committee
1999-2004	Leautaud, Veronica (DBS, Ph.D. program), Thesis Advisory Committee
2000-2004	Park, Sun (ScD, CCB) Thesis Advisory Committee
2001-2005	McLaughlin, Laura (DBS, Ph.D. program), Thesis Advisory Committee
2000	Hooper, Craig (DBS, Ph.D. program), Preliminary Qualifying Exam Committee
2000	Mehta, Devangi (DBS, Ph.D. program), Preliminary Qualifying Exam Committee
2001	McLaughlin, Laura (DBS, Ph.D. program), Preliminary Qualifying Exam

Committee

2001	Lin Chi-Yo (DBS, Ph.D. program), Thesis Defense Committee
2001	Robb, Aisha (DBS, Ph.D. program), Preliminary Qualifying Exam Committee
2001	Han, Jaili (DBS, Ph.D. program), Preliminary Qualifying Exam Committee
2002	Bethke, Lara (DBS, Ph.D. program), Preliminary Qualifying Exam Committee
2002	Geyer, Rory (DBS, Ph.D. program), Preliminary Qualifying Exam Committee
2002	Marsit, Carmen (DBS, Ph.D. program), Preliminary Qualifying Exam Committee
2002	Mertz, Sarah (DBS, Ph.D. program), Preliminary Qualifying Exam Committee
2002	Kim Swan (ScD, CCB) Preliminary Qualifying Exam Committee
2003	Han, Jaili (DBS, Ph.D. program), Thesis Defense Committee
2003	Dony Wang (DBS, Ph.D. program), Thesis Defense Committee
2004	Judi Tsai (DBS, Ph.D. program), Thesis Defense Committee
2004	Aisha Robb (DBS, Ph.D. program), Thesis Defense Committee
2005	Sue Wie (DBS, Ph.D. program), Thesis Defense Committee
2005	McLaughlin, Laura (DBS, Ph.D. program), Thesis Defense Committee
2005	Auerbach, Paul (DBS, Ph.D. program), Thesis Defense Committee
2005	Swan, Kim (ScD, GCD), Thesis Defense Committee
2005	Bethke, Lara (DBS, Ph.D. program), Thesis Defense Committee
2005-2009	Chesella, Ann (DBS, Ph.D. program), Thesis advisory committee
2005-2008	Ulenga Nzovu (DBS, Ph.D. program), Thesis advisory committee.
2005-2009	Jingxian Huang (DBS, Ph.D. program), Thesis advisory committee
2009-	Sophie Liu (IMPG, PhD. Program) Thesis advisory committee

BIBLIOGRAPHY

Original Articles

1. Yuan Z-M, Fenselau C, Dulic DM, Martin W, Emary WB, Brundrett RB, Colvin M, Cotter RJ. Laser desorption electron impact: Application to a study of the mechanism of conjugation of glutathione of cyclophosphamide. *Anal Chem.* 62:868-870, 1990.
2. Yuan Z-M, Smith PB, Brundrett RB, Colvin M, Fenselau C. Glutathione conjugation with phosphoramidate mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry. *Drug Metabolism and Disposition: The Biological Fate of Chemicals* 19:625-629, 1991.
3. Reynolds CA, Fox KM, Yuan Z-M, Lam Y. Biosynthesis of ansatrienin: Stereochemical course of the final reduction step leading to the cyclohexanecarboxylic acid moiety. *J Am Chem. Soc* 113:4339-4340, 1991.
4. Conner JW, Yuan Z-M, Callery PS. Active-site directed irreversible inhibition of diamine oxidase by a homologous series of aziridinyl alkylamines. *Biochem. Pharm.* 44: 1299-1333, 1992.
5. Callery PS, Subramanyam B, Yuan Z-M, Pou S, Geelhaar LA, Reynolds KA. Isotopically sensitive regioselectivity in the oxidative deamination of a homologous series of diamines catalyzed by diamine oxidase. *Chem. Biol. Interaction* 85:15-26, 1992.
6. Yuan Z-M, Egorin MJ, Rosen DM, Callery, PS. Cytotoxic monoaziridinyl spermidines. *Biochem. Pharm.* 47:1587-1592, 1994.
7. Yuan Z-M, Egorin MJ, Rosen MD, Simon MA, Callery PS. Cellular pharmacology of Aziridinyl analogues of spermidine. *Cancer Res* 54:742-748, 1994.

8. Kharbanda S, Saleem A, Datta R, Yuan Z-M, Weichselbaum R, Kufe D. Ionizing radiation induces rapid tyrosine phosphorylation of p34 cdc2. *Cancer Res.* 54:412-414, 1994.
9. Kharbanda S, Yuan Z-M, Rubin E, Weichselbaum R, Kufe D. Activation of the src-like p56/p53 Lyn tyrosine kinase by ionizing radiation. *J Biol. Chem.* 269:20739-20743, 1994.
10. Kharbanda S, Yuan Z-M, Taneja N, Kufe D. p56/p53 Lyn tyrosine kinase activation in mammalian cells treated with mitomycin c. *Oncogene* 9:3005-3011, 1994.
11. Saleem A, Kharbanda S, Yuan Z-M, Kufe D. Monocyte colony-stimulating factor stimulates binding of phosphatidylinositol 3-Kinase to Grb2-Sos complexes in human monocytes. *J Biol. Chem.* 270:10380-10383, 1995.
12. Saleem A, Yuan Z-M, Taneja N, Rubin E, Kufe D, Kharbanda S. Activation of serine/threonine protein kinases and early response 1 gene expression by tumor necrosis factor in human myeloid leukemia cells. *J Immunol.* 154:4150-4156, 1995.
13. Yuan Z-M, Kharbanda S, Kufe D. Arabinofuranosylcytosine activates tyrosine phosphorylation of p34 cdc2 and its association with the src-like p56/p53 Lyn kinases in human myeloid leukemia cells. *Biochemistry* 34:1058-1063, 1995.
14. Kharbanda S, Saleem A, Yuan Z-M, Emoto Y, Prasad K, Kufe D. Stimulation of human monocytes with macrophage colony-stimulating factor induces a Grb2-mediated association of the focal adhesion kinases and dynamin. *Proc Natl Acad Sci USA* 92:6132-6136, 1995.
15. Kharbanda S, Saleem A, Yuan Z-M, Kraeft S, Weichselbaum R, Chen LB, Kufe D. Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53 Lyn tyrosine kinase with p34cdc2. *Cancer Res.* 5:3617-3621, 1996.
16. Yuan Z-M, Huang YY, Whang Y, Sawyers C, Weichselbaum R, Kufe D. Role of c-Abl tyrosine kinase in growth arrest response to DNA damage. *Nature* 38:272-274, 1996.
17. Eiseman JL, Yuan Z-M, Eddington ND, Sentz DL, Callery PS, Egorin MJ. Plasma Pharmacokinetics and Urinary Excretion of the Polyamine Analogue, 1,19-Bis(ethylamino)-5,10,15-triazanonadecane (BE-4-4-4-4, NSC 640506), in CD2F1 mice. *Cancer Chem.and Pharm.* 3:13-21, 1996.
18. Yuan Z-M, Huang YY, Kraeft SK, Chen LB, Kufe D. Interaction of cyclin-dependent kinase 2 and the Lyn tyrosine kinase in cells treated with ara-C. *Oncogene* 1:939-946, 1996.
19. Yuan Z-M, Huang YY, Fan MM, Sawyers C, Kharbanda S, Kufe D. Cytotoxic drugs induce the association of c-Abl tyrosine kinase and tumor supressor p53. *J Biol. Chem.* 27:26457-26460, 1996.
20. Yuan Z-M, Huang YY, Weichselbaum R, Kufe, D. Regulation of DNA-damage induced apoptosis by the c-Abl tyrosine kinase. *Proc Natl. Acad. Sci. USA* 94:1437-1440, 1997.
21. Kharbanda S, Pandey P, Jin S, Inoue S, Bharti A, Yuan Z-M, Weichselbaum R, Weaver D, Kufe D. Functional interaction between DNA-PK and c-Abl in the response to DNA damage. *Nature* 386:732-735, 1997.

22. Yuan Z-M, Utsugisawa T, Huang YY, Ishiko T, Nakada S, Kharbanda S, Weichselbaum R, Kufe D. Inhibition of PI 3-kinase by c-Abl in the genotoxic response. *J Biol. Chem.* 272:23485-23488, 1997.
23. Huang YY, Yuan Z-M, Ishiko T, Nakada S, Utsugisawa T, Kato T, Kharbanda S, Kufe D. Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to ara-C. *Oncogene* 15:1947-1952, 1997.
24. Huang YY, Ishiko T, Nakada S, Kato T, and Yuan Z-M. Role for E2F in DNA damage-induced entry of cells into S phase. *Cancer Res.* 57:3640-3643, 1997.
25. Kharbanda S, Pandey P, Schofield L, Israels S, Roncinske R, Yoshida K, Bharti A, Yuan Z-M, Saxena S, Weichselbaum R, Nalin C, Kufe D. Role for Bcl-x_L as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. *Proc Natl. Acad. Sci. USA* 94:6939-6942, 1997.
26. Yuan Z-M, Utsugisawa T, Ishiko T, Nakada S, Huang YY, Kharbanda S, Weichselbaum R, Kufe D. Activation of protein kinase C delta by the c-Abl tyrosine kinase in response to genotoxic stress. *Oncogene* 16:1643-1648, 1998.
27. Yuan Z-M, Huang YY, Ishiko T, Nakada S, Utsugisawa T, Kharbanda S, Wang R, Sung P, Shinohara A, Weichselbaum R, Kufe D. Regulation of Rad51 function by c-Abl in the response to DNA damage. *J Biol Chem.* 273:3799-3802, 1998.
28. Yuan Z-M, Huang YY, Ishiko T, Nakada S, Utsugisawa T, Shioya H, Utsugisawa Y, Yokoyama K, Weichselbaum R, Shi Y, Kufe D. Role of p300 in stabilization of p53 in the response to DNA damage. *J Biol. Chem* 274:1883-1886, 1999.
29. Huang Y, Nakada S, Ishiko T, Utsugisawa T, Datta R, Kharbanda S, Yoshida K, Talanian RV, Weichselbaum R, Kufe D, and Yuan Z-M. Role for caspase-mediated cleavage of Rad51 in induction of apoptosis by DNA damage. *Mol Cell Biol.* 19:2986-2997, 1999.
30. Yuan Z-M, Huang YY, Ishiko T, Nakada S, Utsugisawa T, Shioya H, Utsugisawa Y, Yokoyama K, Shi Y, Weichselbaum R, Kufe D. Function for p300 but not CBP in the apoptotic response to DNA damage. *Oncogene* 18(41):5714-5717, 1999.
31. Yuan Z-M, Shioya H, Ishiko T, Sun X, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D. p73 is regulated by the c-Abl tyrosine kinase in the apoptotic response to DNA damage. *Nature* 399(6738):814-817, 1999.
32. Gu J, Chen D, Rosenblum J, Rubin RM, Yuan Z-M. Identification of a sequence element from p53 that signals for Mdm2-targeted degradation. *Mol Cell Biol.* 20(4):1243-1253, 2000.
33. Kharbanda S, Pandey P, Yamauchi T, Kumar S, Kaneki M, Kumar V, Bharti A, Yuan Z-M, Ghanem L, Rana A, Weichselbaum R, Johnson G, Kufe D. Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. *Mol Cell Biol.* 20(14):4979-4989, 2000.
34. Kharbanda S, Kumar V, Dhar S, Pandey P, Chen C, Majumder P, Yuan Z-M, Whang Y, Strauss W, Pandita TK, Weaver D, Kufe D. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. *Curr. Biol.* 10(10):568-575, 2000.
35. Kumar V, Sabatini D, Pandey P, Gingras AC, Majumder PK, Kumar M, Yuan Z-M, Carmichael G, Weichselbaum R, Sonenberg N, Kufe D, Kharbanda S. Regulation of the rapamycin and FKBP-

- target 1/mammalian target of rapamycin and cap-dependent initiation of translation by the c-Abl protein-tyrosine kinase. *J Biol. Chem.* 275(15):10779-10787, 2000.
36. Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, Cheng K, Chen YN, Campbell A, Sudha T, Yuan Z-M, Narula J, Weichselbaum R, Nalin C, Kufe D. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. *J Biol. Chem.* 275(1):322-327, 2000.
 37. Zeng X, Li X, Miller A, Yuan Z-M, Yuan W, Kwok RP, Goodman R, Lu H. The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis. *Mol Cell Biol* 20(4):1299-1310, 2000.
 38. Gu J, Rubin R M, Yuan, Z-M. The sequence element of p53 that signals for Mdm2-mediated Degradation is also required for HPV16 E6 and E1B 55k/E4 34k to target p53 for degradation. *Oncogene.* 20: 3519-3527, 2001.
 39. Gu J, Kawai H, Wiederschain D, Yuan Z-M. Mechanism of the functional inactivation in a Li-Fraumeni Syndrome p53 that has a mutation outside of the DNA binding domain. *Cancer Res.* 61:1741-1746, 2001.
 40. Wiederschain D, Gu J, Yuan Z-M. Evidence for a distinct inhibitory factor in the regulation of p53 functional activity. *J Biol. Chem.* 276(30):27999-8005, 2001.
 41. See RH, Calvo D, Shi Y, Kawa H, Luke MP, Yuan Z-M, Shi Y. Stimulation of p300-mediated transcription by the kinase MEKK1. *J Biol. Chem.* 276(19):16310-7, 2001.
 42. Gu J, Nie L, Kawai H, Yuan Z-M. Subcellular distribution of p53 and p73 are differentially regulated by MDM2. *Cancer Res.* 61: 6703-6707, 2001.
 43. Kawai H, Nie L, Wiederschain D, Yuan Z-M. Dual role of p300 in the regulation of p53 stability. *J Biol. Chem.* 276:45928-32, 2001.
 44. Gu J, Nie L, Wiederschain D, Yuan Z-M. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. *Mol Cell Biol.* 21(24):8533-46, 2001.
 45. Shimura T, Inoue M, Taga M, Shiraishi K, Uematsu N, Takei N, Yuan ZM, Shinohara T, Niwa O. p53-dependent S-phase damage checkpoint and pronuclear cross talk in mouse zygotes with X-irradiated sperm. *Mol Cell Biol.* 22(7):2220-8, 2002.
 46. Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G, Yuan ZM. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. *J Biol. Chem.* 277(22):19251-4, 2002.
 47. Kawai H, Nie L, Yuan ZM. Inactivation of NF-kappaB-dependent cell survival, a novel mechanism for the proapoptotic function of c-Abl. *Mol Cell Biol.* 22(17):6079-88, 2002.
 48. Kitao H, Yuan ZM Regulation of ionizing radiation-induced Rad52 nuclear foci formation by c-Abl-mediated phosphorylation. *J Biol. Chem.* 277(50):48944-8, 2002.
 49. Tsai KC & Yuan ZM. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. *Cancer Res.* 15;63(12):3418-24, 2003.

50. Kawai H, Wiederschain D, Yuan ZM. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. *Mol Cell Biol.* 23(14):4939-47, 2003.
51. Wiederschain D, Kawai H, Gu J, Shilatifard A, Yuan ZM. Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL. *Mol Cell Biol.*;23(12):4230-46, 2003.
52. Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM. DNA damage-induced MDMX degradation is mediated by MDM2. *J Biol Chem.* 278(46):45946-53, 2003
53. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. *Nat Genet.* 36(1):55-62, 2004
54. Toyoshima M, Shimura T, Adiga SK, Taga M, Shiraishi K, Inoue M, Yuan ZM, Niwa O. Transcription-independent suppression of DNA synthesis by p53 in sperm-irradiated mouse zygotes. *Oncogene.* 24(20):3229-35; 2005
55. Wiederschain D, Kawai H, Shilatifard A, Yuan ZM. Multiple MLL fusion proteins suppress p53-mediated response to DNA damage. *J Biol. Chem.* 280(26):24315-21, 2005
56. Tsai KKC, Chuang, YYE, Little LB, Yuan ZM. Cellular mechanisms for low-dose ionizing radiation-induced perturbation of the breast tissue microenvironment. *Cancer Res.* 65(15):6734-44, 2005
57. Stuart JR, Kawai H, Tsai KKC, Chuang EY, Yuan ZM. c-Abl regulates Early Growth Response Protein (EGR1) in response to oxidative stress. *Oncogene* 24(55): 8085-92, 2005
58. Stuart JR, Gonzalez FH, Kawai H, Yuan ZM. C-ABL interacts with the wave2 signaling complex to induce membrane ruffling and cell spreading. *J Biol Chem.* 281(42):31290-7, 2006
59. Kim MM, Wiederschain D, Kennedy D, Hansen E, Yuan ZM.. Modulation of p53 and MDM2 activity by novel interaction with Ras-Gap binding proteins (G3BP). *Oncogene* .26(29):4209-15, 2007
60. Kawai H, Lopez-Pajares V, Kim MM, Wiederschain D, Yuan ZM A requirement of RING domain-mediated interaction for MDM2's E3 ligase activity. *Cancer Res.* 67(13):6026-30, 2007
61. Lopez-Pajares V, Kim MM, Yuan ZM. Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding. *J Biol Chem.* 2008 Mar 20;
62. Huang Y, Zhang J, Kim MM, McHenry M, Lopez- Pajares V, Zeng W, Dibble C, Mizgerd J, Yuan ZM. Induction of cytoplasm accumulation of p53, a mechanism for low levels of arsenic exposure to predispose cells to malignant transformation. *Cancer Research* 2008 Nov 15;68(22):9131-6.
63. Cai X and Yuan ZM. Stochastic Simulation of the p53-MDM2/MDMX Loop. *Journal of Computational Biology. J Comput Biol.* 2009 Jul;16(7):917-33.
63. Wu XL, Gu MM, Huang L, Liu XS, Zhang HX, Ding XY, Xu JQ, Cui B, Wang L, Lu SY, Chen XY, Zhang HG, Huang W, Yuan WT, Yang JM, Gu Q, Fei J, Chen Z, Yuan ZM, Wang ZG. Multiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 gene. *Am J Hum Genet.* 2009 Jul;85(1):53-63.
65. Tsai KC, Stuart J, Chuang YY, Little JB and Yuan ZM. Low Dose Radiation-induced Senescent Stromal Fibroblasts Render Nearby Breast Cancer Cells Radio-resistance. *Radiation Research* 2009 Sep;172(3):306-13.

66. Chen L, Li Z, Zwolinska AK, Smith MA, Cross B, Koomen J, Yuan ZM, Jenuwein T, Marine JC, Wright KL, Chen J. MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output. *EMBO J.* 2010 Aug 4;29(15):2538-52. Epub 2010 Jun 29.
67. Hang Su, Kevin Mc Henry, Suthakar Ganapathy, Teng Xu, Long Song, Weiqi Zeng, Rajuli Lall, Miriam Shadfan, and Zhi-Min Yuan. A novel function for Vps34 in regulation of cell proliferation. Under review by *Cancer Cell* 2010.